Table 1 Ligand-binding affinities for TIGIT, CD226, and CD112R.

From: TIGIT, a novel immune checkpoint therapy for melanoma

Ligand/receptor affinity

TIGIT

CD226

CD112R

CD96

CD155

1–3 nM

114-199 nM

/

37.6 nM

CD112

Not measurable

0.31–8.97 µM

88 nM

/

Back to article page